JASMINE: A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) (clinicaltrials.gov) - Sep 25, 2026 - P3 | N=240 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Aug 2028 ➔ Apr 2029 | Trial primary completion date: May 2027 ➔ Jan 2028
Trial completion date • Trial primary completion date • Dermatomyositis • Immunology • Myositis
|